Skip to main content
. 2016 Mar 1;7(14):18469–18484. doi: 10.18632/oncotarget.7841

Figure 9. Schematic representation of MTA1-targeted effects of pterostilbene in prostate cancer.

Figure 9

Significantly increased levels of MTA1, a key upstream epigenetic regulator, promote inflammation, tumorigenesis, EMT, angiogenesis, and survival signaling and repress apoptosis. Pterostilbene (PTER) targets MTA1 and MTA1-guided molecular drivers of tumor promotion, thereby blocking the Pten loss-driven prostate tumorigenesis and cancer progression.